Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

33.62 -1.86 (-5.24%)
Streaming Delayed Price Updated: 12:46 PM EDT, Jun 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
From Legend Biotech Corporation
Via Business Wire
News headline image
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
News headline image
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks? ↗
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments. 
Via Benzinga
News headline image
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
News headline image
Key Takeaways From Legend Biotech Analyst Ratings ↗
 
Via Benzinga
News headline image
Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
News headline image
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
News headline image
The Latest Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Legend Biotech ↗
 
Via Benzinga
News headline image
Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast ↗
 
Via Benzinga
News headline image
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
News headline image
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say ↗
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or  
Via Benzinga
News headline image
Earnings Scheduled For November 20, 2023 ↗
Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million. 
Via Benzinga
News headline image
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
News headline image
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
News headline image
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On ↗
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector. 
Via The Motley Fool
News headline image
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
From Legend Biotech Corporation
Via Business Wire
News headline image
Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug ↗
Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,  
Via Benzinga
News headline image
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
News headline image
3 Biotech Stocks That Analysts Are Drooling Over ↗
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
News headline image
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
From Legend Biotech Corporation
Via Business Wire
News headline image
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
News headline image
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
News headline image
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
News headline image
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
From Legend Biotech
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.